MedTrace Logo

Prediction of Acute Kidney Injury in Patients With COVID-19

NCT04406688 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-11-07

No results posted yet for this study

Summary

The two biomarkers determined in urine, "Tissue Inhibitor of Metalloproteinases 2 (TIMP-2)" and "Insulin-like Growth Factor-Binding Protein 7 (IGFBP7)", can indicate the occurrence of Acute kidney injury (AKI) in cardiac surgery and critically ill patients at an early stage. However, no data are available whether these parameters can also predict the occurrence of AKI in the context of COVID-19 infection. An early prediction of AKI can be helpful for the optimisation of therapeutic management to improve patient outcome and for the triage of patients.

The aim of this observational study is to evaluate whether the biomarker \[TIMP- 2\]\*\[IGFBP7\] can predict the occurrence of AKI in critically ill patients suffering from SARS-CoV2 associated acute respiratory distress syndrome.

Conditions

Sponsors & Collaborators

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Alexander Zarbock, MD · University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-22
Primary Completion
2021-12-30
Completion
2022-03-31

Countries

  • Germany
  • Italy
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04406688 on ClinicalTrials.gov